MALVERN, Penn. , Feb. 3, 2014 /PRNewswire/ -- Unique Generics Product Portfolio, Attractive Pipeline, Builds On Qualitest''s Strength In Controlled Substances Transaction Expected To Be Immediately Accretive To Endo''s Adjusted Diluted EPS Endo ... Asian Hospital & Healthcare Management, 1 month ago
Must-know update: Lone Pine Capital's positions in 4Q 2013 (Part 6 of 8) ( Continued from Part 5 ) Specialty pharmaceutical company Endo Health Solutions (ENDP) is a brand new 1.26% position initiated in the last quarter of 2013 by Lone Pine ...Yahoo! Finance, 1 month ago Millennium Management buys a position in Endo International Yahoo! Finance, 3 weeks ago
MALVERN, Pa., Feb. 20, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its fourth quarter 2013 financial results before the open of the U.S. financial markets on February 28, 2014 and members of its senior management team ...BioSpace, 1 month ago Endo Health Solutions Reports net loss of $776M in fourth quarter 2013 News-Medical.Net, 1 month ago ENDO HEALTH SOLUTIONS INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations TMC Net, 1 month ago Endo Reports Fourth Quarter And Full Year 2013 Financial Results Barchart, 1 month ago
Endo International plc (ENDP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
Summary: Endo reported higher-than-expected earnings but lower-than-expected revenues in the fourth quarter of 2013 primarily due to lower sales of Lidoderm and Opana ER. The company issued disappointing outlooks for 2014 both on revenues as well ...Zacks.com, 2 days ago Endo Health Solutions Receives Neutral Rating from Zacks (ENDP) Mideast Time, 1 month ago Endo Health Solutions's Neutral Rating Reaffirmed at Zacks (ENDP) American Banking News, 1 month ago
Endo Health Solutions ( ENDP ) fourth quarter 2013 earnings (excluding special items) of 96 cents per share edged past the Zacks Consensus Estimate by 2 cents but decreased 41% from the year-ago period. Earnings in the final quarter of 2013 were ...Yahoo! Finance, 1 month ago Endo Health Solutions' CEO Discusses Q4 2013 Results - Earnings Call Transcript Seeking Alpha, 1 month ago
Indian companies performance in the US formulations space was remarkable in Q3FY14 According to KRChoksey Shares and Securities, Indian pharmaceutical companies performance in the US formulations space was remarkable in Q3FY14. The companies have ...Express Pharma, 1 month ago
on your WebpageAdd Widget >Get your members hooked!